Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jinhai Medical TechnologyHKSE:02225 -7.14%61 Days Payable is 62.06 as of Dec. 2025, which is 125% above its 10-year median of 27.59. GuruFocus rates HKSE:02225 with a GF Score™ of 61/100 and a GF Value™ of HK$1.41 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 491 Conglomerates companies, Jinhai Medical Technology ranks better than 73.73% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02225 vs RHI, KFY, TNET: Days Payable Comparison
For the Conglomerates subindustry, Jinhai Medical Technology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jinhai Medical Technology Days Payable vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Jinhai Medical Technology's Days Payable distribution charts can be found below:
* The bar in red indicates where Jinhai Medical Technology's Days Payable falls into.
Jinhai Medical Technology Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Jinhai Medical Technology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jinhai Medical Technology (HKSE:02225) has a Days Payable of 62.06 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jinhai Medical Technology and its competitors. This is 125% above median its historical median of 27.59. Over the past decade, Jinhai Medical Technology's Days Payable has ranged from 6.51 to 125.43. According to the industry distribution chart, Jinhai Medical Technology ranks #129 out of 491 companies in the Conglomerates industry, placing it in the top 26.3%.
Is Jinhai Medical Technology's Days Payable too high?
Jinhai Medical Technology's current Days Payable of 62.06 is 125% above median its 10-year median of 27.59. Over the past 10 years, this metric has ranged from a low of 6.51 to a high of 125.43. The Conglomerates industry median Days Payable is 54.24. Jinhai Medical Technology's value of 62.06 is 14.4% above this industry median. Based on the distribution chart, Jinhai Medical Technology ranks #129 out of 491 companies in the Conglomerates industry, which is above the industry midpoint. Overall, Jinhai Medical Technology has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jinhai Medical Technology's Days Payable compare to RHI and KFY?
According to the Conglomerates industry distribution chart, Jinhai Medical Technology ranks #129 out of 491 companies for Days Payable. This puts Jinhai Medical Technology in the upper half of its industry. The industry median Days Payable is 54.24. Jinhai Medical Technology's value of 62.06 is 14.4% above this benchmark. Historically, Jinhai Medical Technology's own Days Payable has ranged from 6.51 to 125.43 over the past decade. While the company's 10-year median is 27.59 vs. the industry median of 54.24, Jinhai Medical Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Conglomerates company?
The median Days Payable among Conglomerates companies is 54.24, based on 491 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jinhai Medical Technology's current Days Payable of 62.06 is 14.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jinhai Medical Technology and its competitors. For the Conglomerates industry, the median Days Payable is 54.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jinhai Medical Technology's current Days Payable is 62.06, which is 125% above median its own 10-year median of 27.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinhai Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, Jinhai Medical Technology (HKSE:02225) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$1.41, compared to a current price of HK$6.05 — trading 328.7% above its estimated fair value. The current Days Payable is 62.06, which is 125% above median its 10-year median of 27.59 and 14.4% above the Conglomerates industry median of 54.24. Jinhai Medical Technology's overall GF Score™ is 61/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Jinhai Medical Technology (HKSE:02225), the current Days Payable is 62.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jinhai Medical Technology (HKSE:02225) Overvalued in 2026?
Based on GuruFocus' analysis, Jinhai Medical Technology stock appears to be overvalued.
The current stock price of HK$6.05 is trading 328.7% above its estimated GF Value™ of HK$1.41.
GuruFocus considers Jinhai Medical Technology to be Significantly Overvalued.
Key valuation signals for HKSE:02225:
Days Payable: 62.06 (125% above median its 10-year median of 27.59)
GF Value™: HK$1.41 vs. price of HK$6.05 (328.7% above fair value)
Industry Position: 14.4% above the Conglomerates median (#129 of 491)
No single metric tells the full story. See the HKSE:02225 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jinhai Medical Technology Ltd is an investment holding company. Along with its subsidiaries, it is principally engaged in providing medical equipment in China and manpower outsourcing and ancillary services to building and construction contractors in Singapore. The group also provides IT services, construction ancillary services (which comprise warehousing, cleaning, and building maintenance works), and dormitory services in Singapore. It generates maximum revenue from the sale of minimally invasive surgery solutions, medical products, and related services in the People's Republic of China.
61GF Score
Get the complete analysis for HKSE:02225
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02225 has been successfully added to your 
